156 related articles for article (PubMed ID: 30124327)
1. Characterization of Molecular Subtypes of Paget Disease of the Breast Using Immunohistochemistry and In Situ Hybridization.
Wachter DL; Wachter PW; Fasching PA; Beckmann MW; Hack CC; Riener MO; Hartmann A; Strehl JD
Arch Pathol Lab Med; 2019 Feb; 143(2):206-211. PubMed ID: 30124327
[TBL] [Abstract][Full Text] [Related]
2. Molecular markers in Paget disease of the breast.
Fu W; Lobocki CA; Silberberg BK; Chelladurai M; Young SC
J Surg Oncol; 2001 Jul; 77(3):171-8. PubMed ID: 11455553
[TBL] [Abstract][Full Text] [Related]
3. Molecular subtyping of mammary Paget's disease using immunohistochemistry.
Arafah M; Arain SA; Raddaoui EMS; Tulba A; Alkhawaja FH; Al Shedoukhy A
Saudi Med J; 2019 May; 40(5):440-446. PubMed ID: 31056619
[TBL] [Abstract][Full Text] [Related]
4. Different panels of markers should be used to predict mammary Paget's disease associated with in situ or invasive ductal carcinoma of the breast.
Lester T; Wang J; Bourne P; Yang Q; Fu L; Tang P
Ann Clin Lab Sci; 2009; 39(1):17-24. PubMed ID: 19201736
[TBL] [Abstract][Full Text] [Related]
5. Assessment of Her-2/Neu status by immunohistochemistry and fluorescence in situ hybridization in mammary Paget disease and underlying carcinoma.
Anderson JM; Ariga R; Govil H; Bloom KJ; Francescatti D; Reddy VB; Gould VE; Gattuso P
Appl Immunohistochem Mol Morphol; 2003 Jun; 11(2):120-4. PubMed ID: 12777994
[TBL] [Abstract][Full Text] [Related]
6. [Morphological features of basal-like subtype invasive carcinoma of breast].
Gao LX; Yang GZ; Ding HY; Li L
Zhonghua Bing Li Xue Za Zhi; 2008 Feb; 37(2):83-7. PubMed ID: 18681317
[TBL] [Abstract][Full Text] [Related]
7. Reduced E-cadherin expression correlates with disease progression in Paget's disease of the vulva but not Paget's disease of the breast.
Ellis PE; Cano SD; Fear M; Kelsell DP; Ghali L; Crow JC; Perrett CW; MacLean AB
Mod Pathol; 2008 Oct; 21(10):1192-9. PubMed ID: 18469796
[TBL] [Abstract][Full Text] [Related]
8. Using immunohistochemistry to classify the molecular subtypes of Paget's disease of the breast.
Cai Y; Cheng Z; Nangong J; Zheng X; Yuan Z
Cancer Med; 2023 Jul; 12(13):14104-14111. PubMed ID: 37170681
[TBL] [Abstract][Full Text] [Related]
9. Comparison of estrogen receptor, progesterone receptor and HER2 results in concurrent ipsilateral samples with invasive breast carcinoma: a retrospective study of 246 biopsies from 119 patients.
Singh K; Wang Y; Marketkar S; Kalife ET; Steinhoff MM
Hum Pathol; 2017 Jul; 65():123-132. PubMed ID: 28457730
[TBL] [Abstract][Full Text] [Related]
10. [Breast Paget disease: morphologic substrate and Paget cells characteristics].
Oprić D; Granić M; Mujkanović N; Oprić S; Malis M
Med Arh; 2006; 60(3):171-4. PubMed ID: 16719231
[TBL] [Abstract][Full Text] [Related]
11. Mammary Paget's Disease of the Male Breast: A Rare Case With an Unusual Immunohistochemical Profile.
Moore SA; Notgrass HM; Vandergriff TW; Sahoo S
Int J Surg Pathol; 2020 Apr; 28(2):210-215. PubMed ID: 31514589
[TBL] [Abstract][Full Text] [Related]
12. Comparative study of breast cancer with or without concomitant Paget disease: An analysis of the SEER database.
Chen S; Chen H; Yi Y; Jiang X; Lei H; Luo X; Chen Y; Liu S; Yuan D; Jia X; Li J
Cancer Med; 2019 Jul; 8(8):4043-4054. PubMed ID: 31134761
[TBL] [Abstract][Full Text] [Related]
13. Immunocytochemical detection of estrogen receptors in mammary Paget cells.
Tani EM; Skoog L
Acta Cytol; 1988; 32(6):825-8. PubMed ID: 2849272
[TBL] [Abstract][Full Text] [Related]
14. Breast cancer subtypes as defined by the estrogen receptor (ER), progesterone receptor (PR), and the human epidermal growth factor receptor 2 (HER2) among women with invasive breast cancer in California, 1999-2004.
Parise CA; Bauer KR; Brown MM; Caggiano V
Breast J; 2009; 15(6):593-602. PubMed ID: 19764994
[TBL] [Abstract][Full Text] [Related]
15. HER-2 gene amplification in Paget disease of the nipple and extramammary site: a chromogenic in situ hybridization study.
Bianco MK; Vasef MA
Diagn Mol Pathol; 2006 Sep; 15(3):131-5. PubMed ID: 16932067
[TBL] [Abstract][Full Text] [Related]
16. Basal-like immunophenotype markers and prognosis in early breast cancer.
Cassol L; Silveira Graudenz M; Zelmanowicz A; Cancela A; Werutsky G; Rovere RK; Garicochea B
Tumori; 2010; 96(6):966-70. PubMed ID: 21388060
[TBL] [Abstract][Full Text] [Related]
17. Immunohistochemistry of mammary Paget's disease. Cytokeratin 7, GATA3, and HER2 are sensitive markers.
Arain SA; Arafah M; Said Raddaoui EM; Tulba A; Alkhawaja FH; Al Shedoukhy A
Saudi Med J; 2020 Mar; 41(3):232-237. PubMed ID: 32114594
[TBL] [Abstract][Full Text] [Related]
18. Prognosis in women with small (T1mic,T1a,T1b) node-negative operable breast cancer by immunohistochemically selected subtypes.
Cancello G; Maisonneuve P; Rotmensz N; Viale G; Mastropasqua MG; Pruneri G; Montagna E; Dellapasqua S; Iorfida M; Cardillo A; Veronesi P; Luini A; Intra M; Gentilini O; Scarano E; Goldhirsch A; Colleoni M
Breast Cancer Res Treat; 2011 Jun; 127(3):713-20. PubMed ID: 21452022
[TBL] [Abstract][Full Text] [Related]
19. Apocrine carcinoma as triple-negative breast cancer: novel definition of apocrine-type carcinoma as estrogen/progesterone receptor-negative and androgen receptor-positive invasive ductal carcinoma.
Tsutsumi Y
Jpn J Clin Oncol; 2012 May; 42(5):375-86. PubMed ID: 22450930
[TBL] [Abstract][Full Text] [Related]
20. Paget's disease of the male breast--report of a case and histopathologic study.
Sano Y; Inoue T; Aso M; Hagari Y; Hattori K; Shimao S; Notsu T
J Dermatol; 1989 Jun; 16(3):237-41. PubMed ID: 2551944
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
